WS #16341
L'Oréal reported its fastest sales growth in 2.5 years (+7.7%), driven by a 10%+ surge in China and resilient luxury demand, outperforming peers like Kering which warned that H2 margins will not improve. This divergence highlights a bifurcation in the luxury market where premium beauty remains robust while fashion and discretionary goods face headwinds. Investors are rotating into defensive consumer staples and beauty leaders like LRLCY and EL. Moderna shares halted trading after an unconfirmed report suggested its personalized mRNA cancer vaccine combined with pembrolizumab could reduce melanoma recurrence, causing an 11.86% drop on volatility. This event underscores the market's fragility regarding unverified biotech catalysts. Concurrently, an unethical vaccine trial backed by RFK Jr. was formally canceled, adding to the regulatory uncertainty surrounding the healthcare sector.
Consumer Resilience vs Luxury Pressure
L'Oréal reported its fastest sales growth in 2.5 years (+7.7%), driven by a 10%+ surge in China and resilient luxury demand, outperforming peers like Kering which warned that H2 margins will not improve. This divergence highlights a bifurcation in the luxury market where premium beauty remains robust while fashion and discretionary goods face headwinds. Investors are rotating into defensive consumer staples and beauty leaders like LRLCY and EL.
Moderna shares halted trading after an unconfirmed report suggested its personalized mRNA cancer vaccine combined with pembrolizumab could reduce melanoma recurrence, causing an 11.86% drop on volatility. This event underscores the market's fragility regarding unverified biotech catalysts. Concurrently, an unethical vaccine trial backed by RFK Jr. was formally canceled, adding to the regulatory uncertainty surrounding the healthcare sector.